BioCryst PharmaceuticalsBCRX
BCRX
About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Employees: 531
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
96% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $6.44M
39% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 38
21% more capital invested
Capital invested by funds: $1.09B [Q2] → $1.31B (+$225M) [Q3]
6% more funds holding
Funds holding: 240 [Q2] → 255 (+15) [Q3]
5% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 74
1.79% less ownership
Funds ownership: 85.25% [Q2] → 83.46% (-1.79%) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
4%
upside
Avg. target
$10.67
39%
upside
High target
$14
83%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
RBC Capital Brian Abrahams 14% 1-year accuracy 11 / 79 met price target | 30%upside $10 | Outperform Reiterated | 5 Nov 2024 |
Needham Serge Belanger 37% 1-year accuracy 47 / 126 met price target | 83%upside $14 | Buy Reiterated | 5 Nov 2024 |
Barclays Gena Wang 10% 1-year accuracy 3 / 30 met price target | 4%upside $8 | Equal-Weight Maintained | 5 Nov 2024 |
Financial journalist opinion
Positive
Seeking Alpha
2 weeks ago
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
BioCryst remains a "Buy" due to ORLADEYO's proven success, potential growth, and management's confidence despite significant competition and a one-dimensional revenue stream. Q3 2024 showed mixed results with a modest revenue beat and slight earnings miss, leading to a 13% stock drop on higher volume. ORLADEYO's revenue guidance is strong, with expectations of reaching $1 billion annually by 2029, driven by its convenience and efficacy.
Neutral
GlobeNewsWire
3 weeks ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 17,400 shares, and restricted stock units (RSUs) covering an aggregate of 12,150 shares, of BioCryst common stock. The options and RSUs were granted as of November 29, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
Neutral
GlobeNewsWire
1 month ago
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Neutral
GlobeNewsWire
1 month ago
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 18,200 shares, and restricted stock units (RSUs) covering an aggregate of 12,750 shares, of BioCryst common stock. The options and RSUs were granted as of October 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
Seeking Alpha
1 month ago
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Jinky Rosselli - Chief Data and Insights Officer Conference Call Participants Nick Lenard - JPMorgan Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Maury Raycroft - Jefferies Stacy Ku - TD Cowen Liisa Bayko - Evercore ISI Gena Wang - Barclays Serge Belanger - Needham & Company Operator Good day and Welcome to the BioCryst Third Quarter 2024 Earnings Call. All participants will be in listen-only mode.
Neutral
Zacks Investment Research
1 month ago
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Positive
Zacks Investment Research
2 months ago
How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%
The consensus price target hints at a 79.5% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
2 months ago
BioCryst to Report Third Quarter 2024 Financial Results on November 4
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, 2024.
Neutral
GlobeNewsWire
2 months ago
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with ORLADEYO.
Charts implemented using Lightweight Charts™